MediciNova
MediciNova is a biopharmaceutical company focused on acquiring and developing small-molecule therapeutics for diseases with unmet medical needs, with emphasis on the United States market. Its diverse pipeline includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for neurological disorders; MN-221 (bedoradrine) for acute asthma exacerbations; MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin-binding agent for solid tumors. The company pursues collaborations and alliances to advance its portfolio, including vaccine development efforts with BioComo and Mie University and partnerships with Japanese pharmaceutical companies. Development efforts focus on neurology, fibrosis, and oncology, aiming to address medical needs through clinical and preclinical programs.
Top Regions
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
1 past transactions
Avigen
Acquisition in 2009
Avigen, Inc., a biopharmaceutical company, engages in identifying and developing products to treat patients with neurological and other disorders. The company develops the AV411 portfolio, which includes the phase II-stage lead drug compound and proprietary analogs and represents novel, non-opioid drugs for the treatment of various large pain and drug addiction indications. AV411 is an orally bioavailable small molecule; a glial attenuator that suppresses pro-inflammatory cytokines IL-1 beta, TNF alpha, and IL-6; and a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. AV411 is being evaluated in Phase Ib/IIa clinical trials. The company was founded in 1992 and is headquartered in Alameda, California. As of December 18, 2009, Avigen, Inc. operates as a subsidiary of MediciNova Inc
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.